Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-05-25 Legal Proceedings Report
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
Legal Proceedings Report Classification · 1% confidence The document is a press release dated May 25, 2020, announcing that Abivax received German regulatory approval (from BfArM) for its Phase 2b/3 clinical trial of ABX464 for COVID-19. It details the trial scope, funding, and quotes the CEO and a lead investigator. This type of announcement, detailing clinical trial progress, regulatory milestones, and associated financing/development updates, is characteristic of an Earnings Release (ER) or a general corporate news announcement. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific management/board change, and it focuses on key operational/clinical progress, 'ER' (Earnings Release) is the closest fit among the options for a significant corporate update, although 'RNS' (Regulatory Filings) is also plausible as a general news item. Given the focus on a major clinical trial milestone and associated funding, it functions as a key corporate update, often released alongside or in lieu of standard earnings reports when major news breaks. However, since it is a news announcement about a clinical trial approval, and not explicitly an 'Earnings Release' summarizing financial performance, 'RNS' (Regulatory Filings/General News) is the most appropriate fallback for a specific corporate development announcement that doesn't fit the financial reporting codes (10-K, IR, ER). I will classify it as RNS as it is a general corporate news release about a regulatory/clinical event.
2020-05-25 English
URD 2020
Annual Report Classification · 1% confidence The document is a 'Document d'Enregistrement Universel' (Universal Registration Document), which is the French regulatory equivalent of an Annual Report (10-K). It contains comprehensive financial statements, management reports, governance details, and risk factors for the fiscal year. It is not an announcement of a report, but the report itself, and it is far too substantial to be an RPA or RNS. FY 2020
2020-05-22 French
Abivax postpones its Annual General Meeting to June 19, 2020
AGM Information Classification · 1% confidence The document is a news release announcing the postponement of the Annual General Meeting (AGM) from June 5, 2020, to June 19, 2020. It explicitly mentions 'AGM/EGM' as a keyword and discusses the scheduling of the 'Shareholders meeting'. While it mentions the 'Publication and Release of the 2019 Annual Financial Report' on a different date, the primary subject and headline of this specific announcement is the change in the AGM date. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (5644 chars) is substantial enough that it is not merely a placeholder announcement (RPA/RNS) for the AGM itself, but rather the official communication regarding the AGM logistics.
2020-05-20 English
ABIVAX: 36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated May 15, 2020, announcing that ABIVAX secured €36 million in non-dilutive funding from Bpifrance for its ABX464 Covid-19 program. The text explicitly mentions 'DGAP-News' and contains key financial/corporate news elements like funding details, clinical trial updates, and executive commentary. This format—a brief announcement detailing significant corporate news (financing) without being a comprehensive annual or quarterly report—aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of a major corporate event (financing) rather than just a general regulatory update, and it provides the key highlights immediately, 'ER' (Earnings Release) is often used broadly for major periodic financial/corporate news announcements in some databases, but 'CAP' (Capital/Financing Update) is the most precise fit for funding news. Given the options, 'CAP' is the most specific and accurate classification for an announcement focused entirely on securing financing.
2020-05-15 English
ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
Regulatory Filings Classification · 1% confidence The document is a press release dated May 14, 2020, originating from ABIVAX, announcing scientific study results regarding its drug candidate ABX464's effect on SARS-CoV-2 replication. It uses standard press release formatting, includes contact information, and contains a disclaimer typical of corporate news releases. It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT) or a formal financial report (IR, AR). Since it is an announcement of scientific/study results, it fits best under the general category of corporate news or regulatory announcements that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement disseminated via services like DGAP, especially when the content is primarily operational/scientific news rather than a specific financial report or management change. It is not an Earnings Release (ER) as it focuses on R&D results, not period financials.
2020-05-14 English
Abivax postpones the publication of the yearly universal registration document ('URD')
Report Publication Announcement Classification · 1% confidence The document is a short news release dated April 29, 2020, titled "Abivax postpones the publication of the yearly universal registration document (‘URD’)". The text explicitly states that the company is postponing the release of its 'Universal Registration Document 2020 (URD)' until the end of May. Since the document is an announcement *about* the publication of a report (the URD) rather than the report itself, and it is a general regulatory announcement disseminated via DGAP, it fits the definition of a Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS). Given the specific nature of announcing the publication schedule/delay of a major report, RPA is the most precise fit, as per Rule 2 (The 'MENU VS MEAL' Rule). The URD is a comprehensive annual filing, but this document is only the announcement of its timing.
2020-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.